top of page

ENSAYOS PRÓXIMOS 

Captura de pantalla 2024-09-23 183712.png
Filtrar por AREA
Filtrar por ESTADO

MINT-C

LUCIA GARCIA

CEFALEA

FASE:

III

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine

MINT-E

LUCIA GARCIA

CEFALEA

FASE:

III

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine

NX-BRI-002

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

IV

Non-interventional, prospective, multicenter, European study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice

CATALPA

TERESA MUÑOZ

TRASTORNOS MOV.

FASE:

II

A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

CLOU064C12306

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

III

Efficacy and safety of remibrutinib after switching from ocrelizumab in people living with relapsing multiple sclerosis

PHENOALS-001

VIRGINIA REYES

NEUROMUSCULAR

FASE:

II

A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi- Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS).

PRAX-628-212

PEDRO SERRANO

EPILEPSIA

FASE:

II

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

M24-304

VIRGINIA REYES

NEUROMUSCULAR

FASE:

III

A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Extension to Assess the Efficacy and Safety of Fosigotifator for the Treatment of Amyotrophic Lateral Sclerosis

Illuminate

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

ND

Estudio para evaluar la usabilidad de la introducción de soluciones digitales integrales en la práctica clínica y el valor de su uso en la atención médica de los pacientes con esclerosis múltiple

CLNP023Q12301

GUILLERMINA GARCIA

NEUROMUSCULAR

FASE:

III

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase

Prasinezumab

LUCIA GARCIA

TRASTORNOS MOV.

FASE:

III

A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early parkinson’s disease

NXPLEVE

PEDRO SERRANO

EPILEPSIA

FASE:

III

A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy

NVG-2089-201

GUILLERMINA GARCIA

NEUROMUSCULAR

FASE:

II

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

LP352-301

PEDRO SERRANO

EPILEPSIA

FASE:

III

Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de LP352 en el tratamiento de convulsiones en niños y adultos con encefalopatías epilépticas y del desarrollo

LP352-302

PEDRO SERRANO

EPILEPSIA

FASE:

III

Un estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia, seguridad y tolerabilidad de LP352 en el tratamiento de convulsiones en niños y adultos con síndrome de Dravet

MN44358

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

IV

Estudio para evaluar la usabilidad de la introducción de soluciones digitales integrales en la práctica clínica y el valor de su uso en la atención médica de los pacientes con esclerosis múltiple

CLIN-10200-455

BEATRIZ FERNANDEZ

TRASTORNOS MOV.

FASE:

II

A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled Sequential Cohort Study to Evaluate the Efficacy and Safety of Two Single Doses of IPN10200 for the Treatment of Blepharospasm in Adults

CVHB937B12201

VIRGINIA REYES

NEUROMUSCULAR

FASE:

II

Un estudio de fase 2 controlado con placebo de VHB937 en la esclerosis lateral amiotrófica (ELA) durante 40 semanas seguido de una extensión abierta

CLOU064O12301

VIRGINIA REYES

NEUROMUSCULAR

FASE:

III

Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad del remibrutinib en pacientes con miastenia grave generalizada seguido de una fase de extensión abierta

ARODM1-1001

VIRGINIA REYES

NEUROMUSCULAR

FASE:

I/II

Un estudio de fase 1/2a de escalamiento de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de aro-dm1 en sujetos con distrofia miotónica tipo 1 que tienen ≥18 a ≤65 años

67896153MSC3001

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

III

Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis

ABP 692

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

III

Un estudio de grupo paralelo, aleatorizado, doble ciego para comparar Farmacocinética, farmacodinamia, efectos clínicos y seguridad entre ABP 692 y Ocrevus (Ocrelizumab) en sujetos con esclerosis múltiple remitente recurrente.

MODERNA MS

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

II

A phase 2, randomized, observer-blind, placebo-controlled, dose-ranging study of mRNA-1195 intramuscular injection in participants 18 to ≤55 years of age with early MS

MAVENAGE

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

IV

A prospective observational study to evaluate the effectiveness and safety profile of cladribine tablets in a real-world cohort of relapsing multiple sclerosis patients older and younger than 50 years

COVIDGONITIVO

PEDRO SERRANO

DETERIORO COGNITIVO

FASE:

ND

Randomized placebo-controlled, double-blind clinical trial to investigate treatment effects and safety of Ginkgo biloba extract EGb 761® in participants with cognitive impairment associated with post-COVID-19 syndrome

IGM-2644-101

VIRGINIA REYES

NEUROMUSCULAR

FASE:

I

A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGM-2644 in Participants with Myasthenia Gravis

EFC18098

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

III

A randomized, phase III, open label study to investigate pharmacokinetics, safety, radiological and clinical effects of subcutaneous frexalimab (SAR441344) compared to intravenous frexalimab in adult participants with multiple sclerosis.

CYTB323R12101

ANA ALONSO

ESCLEROSIS MULTIPLE

FASE:

I/II

An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with progressive Multiple Sclerosis (PMS)

AR1001-ADP3-US01

PEDRO SERRANO

ALZHEIMER

FASE:

III

Phase III Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s.

ARGX-113-2315

VIRGINIA REYES

NEUROMUSCULAR

FASE:

III

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis

ARGX-113-2308

VIRGINIA REYES

NEUROMUSCULAR

FASE:

III

A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).

bottom of page